77.6%, P = 0.02124), it demonstrated a clear trend favouring immunotherapy.
← all excerpts
Feasibility and safety of video-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A single-centre experience.
2
—
—
The sentences
The CheckMate-816 study, which investigated the efficacy and safety of neoadjuvant nivolumab combined with chemotherapy compared to chemotherapy alone in patients with resectable stage IB-IIIA NSCLC, demonstrated that adding nivolumab significantly improved pathological response rates and event-free survival, although the OS benefit did not reach statistical significance.